AI-generated analysis. Always verify with the original filing.
Grace Therapeutics announced its third quarter fiscal 2026 financial results for the period ended December 31, 2025, reporting a net loss of $2.3 million. The company also provided a business update, highlighting the FDA's PDUFA target date of April 23, 2026, for its NDA for GTx-104 in the treatment of aneurysmal subarachnoid hemorrhage.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan
Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated February 12, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL do
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $2.30 | |
| Diluted EPS | $-0.14 | |
| Research and Development Expenses | $0.50 | |
| General and Administrative Expenses | $2.00 |